CEL-SCI Stock Forecast, Price & News

-0.04 (-0.18 %)
(As of 06/22/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume467,368 shs
Average Volume1.07 million shs
Market Capitalization$910.18 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CEL-SCI logo


CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.49 out of 5 stars

Medical Sector

1669th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

181st out of 198 stocks

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

What stocks does MarketBeat like better than CEL-SCI?

Wall Street analysts have given CEL-SCI a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CEL-SCI wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for CEL-SCI

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) announced its quarterly earnings data on Sunday, May, 16th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.30. CEL-SCI had a negative net margin of 5,406.61% and a negative trailing twelve-month return on equity of 129.71%.
View CEL-SCI's earnings history

How has CEL-SCI's stock price been impacted by Coronavirus (COVID-19)?

CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CVM shares have increased by 127.2% and is now trading at $22.13.
View which stocks have been most impacted by COVID-19

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

CEL-SCI shares reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:
  • Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 62, Pay $825.53k)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 70, Pay $383.35k)
  • Dr. Eyal Talor, Chief Scientific Officer (Age 65, Pay $317.48k)
  • Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 80, Pay $248.54k)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 79, Pay $237.04k)

Who are some of CEL-SCI's key competitors?

What other stocks do shareholders of CEL-SCI own?

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.39%), D. E. Shaw & Co. Inc. (3.05%), Geode Capital Management LLC (1.50%), Northern Trust Corp (0.97%), D.A. Davidson & CO. (0.81%) and Commonwealth Equity Services LLC (0.58%). Company insiders that own CEL-SCI stock include Geert R Kersten, John Cipriano, Patricia B Prichep and Peter R Young.
View institutional ownership trends for CEL-SCI

Which institutional investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Credit Suisse AG, Goldman Sachs Group Inc., Morgan Stanley, Ameriprise Financial Inc., BNP Paribas Arbitrage SA, AQR Capital Management LLC, and Alliancebernstein L.P..
View insider buying and selling activity for CEL-SCI
or view top insider-selling stocks.

Which institutional investors are buying CEL-SCI stock?

CVM stock was acquired by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Citigroup Inc., Rafferty Asset Management LLC, BlackRock Inc., Geode Capital Management LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, and Russell Investments Group Ltd.. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Patricia B Prichep, and Peter R Young.
View insider buying and selling activity for CEL-SCI
or or view top insider-buying stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $22.13.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $910.18 million and generates $560,000.00 in revenue each year. The company earns $-30,250,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

Where are CEL-SCI's headquarters?

CEL-SCI is headquartered at 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460 or via email at [email protected]

This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.